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While KRAS activation is a fundamental initiating event in
the aetiopathogenesis of pancreatic ductal adenocarcinoma
(PDA), environmental factors influencing the occurrence
and persistence of KRAS mutations remain largely un-
known. The objective was to test the hypothesis that in PDA
there are aetiopathogenic relationships among concentra-
tions of some organochlorine compounds (OCs) and the
mutational status of the KRAS oncogene, as well as among
the latter and coffee intake. Incident cases of PDA were
interviewed and had blood drawn at hospital admission
(N 5 103). OCs were measured by high-resolution gas
chromatography with electron capture detection. Cases
whose tumours harboured a KRAS mutation had higher
concentrations of p,p#-dichlorodiphenyltrichloroethane
(DDT), p,p#-dichlorodiphenyldichloroethene (DDE) and
polychlorinated biphenyls (PCBs) 138, 153 and 180 than
cases with wild-typeKRAS, but differences were statistically
significant only for p,p#-DDT and PCBs 138 and 153. The
association between coffee intake and KRAS mutations
remained significant (P-trend < 0.015) when most OCs
where accounted for. When p,p#-DDT, PCB 153, coffee
and alcohol intake were included in the same model, all were
associated with KRAS (P 5 0.042, 0.007, 0.016 and 0.025,
respectively). p,p#-DDT, p,p#-DDE and PCB 138 were
significantly associated with the two most prevalent KRAS
mutations (Val and Asp). OCs and coffee may have
independent roles in the aetiopathogenesis of PDA through
modulation of KRAS activation, acquisition or persistence,
plausibly through non-genotoxic or epigenetic mechanisms.
Given that KRAS mutations are the most frequent abnor-
mality of oncogenes in human cancers, and the lifelong
accumulation of OCs in humans, refutation or replication of
the findings is required before any implications are assessed.
Introduction
Over three decades of research has yielded a wealth of
knowledge on the biology of ras effects, but very little on their
environmental influences. Today, ras genes are deemed the
most commonly activated oncogenes in human cancer, and
alterations in KRAS are the object of intense scientific scrutiny
(1–3). Yet, a complete understanding of ras function is still to
come (1) and ‘concepts that once seemed on the verge of
comprehension have evolved such that elegant complexity
coupled with hopeless confusion better defines our current state
of knowledge’ (2).
Mutation of oncogenes in the ras family has been associated
with exposure to environmental carcinogens (3). In the early
1980s, ras genes were discovered to be activated by point
mutation, ras mutations were identified in experimental
tumours of rodents exposed to chemical or physical carci-
nogens and evidence accrued on the involvement of the
mutations in the initiation of carcinogenesis; the mutations
were later shown to be essential for tumour development and
maintenance (1–4). Once the oncogenic nature and properties
of ras genes were established, basic research on the
environmental causes of their mutations waned. Fortunately,
molecular pathology and molecular epidemiological studies
contributed additional evidence on the potential role of genetic,
clinical and environmental interactions in the occurrence and
persistence of ras mutations in several human cancers, most
notably, pancreatic, colon and lung adenocarcinomas (5–28).
Some evidence suggests that pancreatic intraepithelial neo-
plasia (PanIN) lesions are precursors of pancreatic ductal
adenocarcinoma (PDA). While several dimensions are being
tested of a PanIN–PDA progression model, most studies
indicate that KRAS mutations precede genetic alterations at the
p16INK4A or Tp53 loci (4,29). KRAS mutations are an
initiating step in PDA pathogenesis (4). However, knowledge
is still limited on factors—particularly, environmental
factors—that influence the occurrence of KRAS mutations,
the expansion of mutant cells and the initiation and progression
of PDA (4). Eventually, such knowledge should both clarify
biological mechanisms and enable a more effective primary
prevention of PDA (5).
Ten years ago, we published two reports suggesting that some
organochlorine compounds (OCs) (7) and coffee intake (8) might
play a role in the pathogenesis of pancreatic cancer through
modulation of KRAS activation or maintenance. While we
stressed that findings required replication, their potential mecha-
nistic relevance received considerable attention (13,15,20–
23,30). First, findings on OCs (7) were deemed to show ‘for
the first time that a mutation of a ras gene was associated with
serum concentrations of OCs in any group of cancer patients’
(31). Second, ‘following recent conflicting but intriguing results
thrown up by rodent and cell culture research about the effects
of caffeine and coffee’ (32), the association between coffee
intake and KRAS (8) was considered to be ‘shown for the first
time in people suffering from pancreatic cancer’ (32).
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OCs are of concern because of their persistence, prevalence
in humans and potential role in contributing to increase risks of
some diseases, including PDA and other cancers (5,7,9,20,33–
48). OCs have a variety of effects on physiological, cellular and
molecular processes that are relevant in cancer aetiopatho-
genesis: induction of enzymes that activate procarcinogens,
interference with DNA repair, provision of a growth advantage
to mutated cells, disruption of cell-cycle checkpoints and
apoptosis and probably epigenetic effects (5,7–9,12,20,33–
43,48–53). However, research on OCs, KRAS and pancreatic
cancer has been limited, and conclusions on mechanistic,
clinical or public health implications would be premature
(5,7,25).
The present paper improves our previous reports (7,8,54) in
five directions, as follows: (i) we double the number of patients
with results on OCs (from 51 to 103); (ii) we adjust the
relationship between coffee intake and KRAS mutations by OC
concentrations; (iii) we also adjust the relationship between
alcohol intake and KRAS mutations by OC concentrations; (iv)
we adjust the relationships between the two main exposures
(OCs and coffee) and KRAS by PDA symptoms and (v) when
assessing the relationships between the two main exposures
and KRAS, we also take into account the influence of past
medical conditions such as diabetes, pancreatitis and peptic
ulcer. The objective of the present analyses was to test the
hypothesis that in PDA mechanistic relationships exist among
concentrations of some OCs and the prevalence at diagnosis of
mutations in the KRAS oncogene, as well as among the latter
and coffee intake.
Materials and Methods
Study population
Methods and strategies of analysis of the PANKRAS II study have been
described in detail (7,8,12,19,24–26,54–68). Briefly, subject recruitment took
place between 1992 and 1995 at five general hospitals in the eastern
Mediterranean part of Spain, where 185 incident cases of PDA were
prospectively identified. The present report is based on 103 PDA patients:
they stem from patients in whom KRAS status was determined (N 5 121), who
had results on serum concentrations of OCs (N 5 144) and who had
information on potential confounders (obtained from patient interviews and
medical records, N 5 165). There were no significant differences between the
103 and the remaining cases in a broad range of sociodemographic and clinical
variables (including sex, education, occupation, hospital, tumour stage, signs
and symptoms of pancreatic cancer, energy intake, diet, consumption of coffee,
tobacco and alcohol and duration of the interview), except that the included
cases were slightly younger (8,12,19,54,57,58,61–64,68). All cases were
reviewed by a panel of experts and by the study reference pathologists, blinded
to the original diagnoses and to molecular results (55,60,65). Twenty-nine
conventional hospital controls were recruited at one of the study hospitals
among subjects admitted for benign, non-digestive disorders unrelated to
tobacco and alcohol consumption (7,24,26,54,68). The ethics committees of
participating hospitals approved the study protocol, and patients gave informed
consent to participate.
Clinicopathological information and personal interviews
More than 94% of the 103 cases were interviewed face-to-face by trained
monitors during hospital stay, close to the time of diagnosis. The respondent
was the patient itself in 96.9% of the cases and a relative alone in 3.1%.
Interviews included questions about past clinical history, signs and symptoms
of pancreatic cancer, occupation, diet and coffee, alcohol and tobacco
consumption (7,8,59,61–64,68). A structured form was used to collect
clinicopathological information from medical records, including details on
diagnostic procedures, signs and symptoms of pancreatic cancer, tumour stage,
laboratory results and follow-up (55,60,61,67). Histological type was classified
according to the International Classification of Diseases for Oncology. All
items concerning the presence of signs and symptoms were further reviewed by
two experienced oncologists and checked for consistency (59). Cholestatic
syndrome involved jaundice, hypocholia (clay-coloured stools) and choluria
(dark brown urine). The constitutional syndrome comprised fatigue, anorexia
and weight loss (59,61,65). Lower lipid-corrected concentrations of six
of the seven OCs analyzed [p,p#-dichlorodiphenyldichloroethene (DDE),
three polychlorinated biphenyls (PCBs), hexachlorobenzene (HCB) and
b-hexachlorocyclohexane (b-HCH)] were observed in patients with cholestatic
syndrome (61); the constitutional syndrome increased only p,p#-dichlorodi-
phenyltrichloroethane (DDT) (61). When symptoms were considered, stage had
only weakly inverse relationships with OC levels (61). The effects of symptoms
on p,p#-DDE, p,p#-DDT and the three PCBs remained significant after
adjusting by the interval from first symptom of PDA to blood extraction (ISE)
and even when further adjusting by stage (61,65).
Detection of KRAS mutations
Details of laboratory protocols have also been described elsewhere (7,8,12,19).
Briefly, mutations in codon 12 of KRAS oncogene were studied using DNA
extracted from paraffin-embedded tumour tissue. Amplifications were done in
two steps by nested polymerase chain reaction; an artificial BstNI restriction
endonuclease site was introduced to discriminate between wild-type and
mutated KRAS codon 12 sequences. Products were analyzed by acrylamide gel
electrophoresis and ethidium bromide staining. This technique was able to
detect one homozygous mutated cell in the presence of 102 normal cells. To
characterize the nucleotide substitution in codon 12, all mutated samples were
further analyzed using a similar restriction fragment length polymorphism-
based approach. Interpretation of digestion products’ electrophoresis was
performed independently by two investigators to confirm the results. The
spectrum of KRAS mutations was available for 40 of the 81 mutated cases
(7,8,12,19).
Analysis of serum concentrations of OCs
The 10-ml screw-capped Pyrex centrifuge tubes capped with Teflon septa were
used to keep and digest the samples (7,57,58,62,69). About 50 ll of the
surrogate solution [0.36 lg/l of 1,2,4,5-tetrabromobenzene (TBB) and 0.52 lg/
l of PCB 209] was added to 2 ml aliquots of serum in the same Pyrex centrifuge
tubes where the samples were stored. Acid digestion of the mixture was
performed by addition of 3 ml of n-hexane and 2 ml of concentrated sulphuric
acid. Gas chromatography analyses were performed with a Hewlett–Packard
model 5890A provided with an electron capture detection and a 30-m  0.25-
mm i.d. DB-5 column (J & W Scientific, Folsom, CA; film thickness 0.25 lm).
A fused silica precolumn of 2 m  0.32 mm i.d. was used and renewed every
30 samples. Selected samples were analyzed by negative-ion chemical
ionization gas chromatography–mass spectrometry with a Fisons MD 800.
The linear range of the detector was determined from injection of standard
mixtures. Calibration lines were performed for all OCs mentioned above. These
compounds were then quantitated in the samples by the external standard
method after replicate analysis. The concentrations of HCB and b-HCH were
corrected for volatility losses using TBB as internal standard. The recoveries of
TBB and PCB 209 were 102% (4.2) and 93% (1.8), respectively. The
recoveries of spiked serum samples were 74–86% for pentachlorobenzene and
HCB, 92–93% of DDTs, 81–95% for HCHs and 77–110% for PCBs. Statistical
analyses were limited to compounds that were detected above the detection
limit in .85% of cases: p,p#-DDT was detected in 87.4% of the 103 PDA
patients and PCB 138 in 95.2%, whereas p,p#-DDE, PCBs 153 and 180, HCB
and b-HCH were detected in all cases.
Analysis of serum concentrations of lipids
Total cholesterol and triglycerides’ levels were determined enzymatically
(CHOD-PAP and GPO-PAP methods, respectively) using serum obtained at the
same time than the serum used for the organochlorine analyses. Total serum
lipids were calculated by the standard short formula (or Standard formula 2) of
Phillips et al. (70,71). Organochlorine concentrations were individually
corrected for total lipids and are expressed in nanograms per gram lipid
(7,62–64,66). Cases and controls had similar concentrations of total cholesterol,
triglycerides and total lipids (63). Correlations among OCs have also been
published (62).
Statistical analysis
In this case–case study (72), we compared serum concentrations of OCs and
coffee intake in 81 cases of PDA with a KRAS-mutated tumour and 22 cases of
PDA whose tumours did not harbour such mutations. Cases with and without
KRAS mutations did not differ significantly in age, sex, education, hospital,
duration of the interview, tumour stage, signs and symptoms of pancreatic
cancer, ISE, energy intake and smoking (8,12,19,25,54–68). To estimate the
direction of the case–case association (7,24,26,72), case–control analyses
compared all 103 cases with the 27 controls with OCs determined. Univariate
statistics were computed as customary (73). For comparisons between
continuous variables, Mann–Whitney’s U-test was used. In contingency tables,
Fisher’s exact test for homogeneity or independence was applied to assess the
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relationship between two categorical variables. OC concentrations were
categorized in tertiles based on all cases with OC results. Receiver operator
characteristic (ROC) curves were constructed to dichotomize OC concen-
trations. To estimate the magnitude of the associations, multivariate-adjusted
odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were
calculated by unconditional logistic regression. Categorical ordinal variables
were analyzed for a linear dose–response relation through the multivariate
analogue of Mantel’s extension test; when a linear trend was not apparent, the
probability test was used. Age, sex, tumour stage and ISE were assessed in all
models as potential confounders (63). Because of findings mentioned above
(61,65), the constitutional syndrome and the cholestatic syndrome were assessed
for inclusion in all models. Other possible confounding variables were also
retained in the models when they materially altered the estimates, such
confounders included alcohol, pancreatitis, peptic ulcer and diabetes mellitus (the
latter four if diagnosed 2 years before PDA) (54,67). Final models were chosen
coherently with the nature of the variables and the study objectives. The level of
statistical significance was set at 0.05, and all tests are two tailed. Analyses
were performed using SPSS, version 12.0 (SPSS Inc., Chicago, IL, 2003).
Results
Cases with a KRAS mutation had higher concentrations of p,p#-
DDT, p,p#-DDE and PCBs 138, 153 and 180 than cases with
wild-type KRAS, but differences were statistically significant
only for p,p#-DDT and for PCBs 138 and 153 (Table I). A
dose–response pattern was approximately linear only for PCB
138 (ORs of 2.8 and 5.1 for the second and third tertiles,
P-trend 5 0.012). Patients in the mid-tertile of p,p#-DDT were
over 29 times more likely to have a KRAS-mutated PDA than
patients in the lower tertile, whereas the OR was only 2.8 in the
upper tertile (Table I, Model 1). Most ORs increased slightly
when adjusted by symptoms (Table I, Model 2). There was no
association between the mutation status of the KRAS gene and
the DDT:DDE ratio nor with concentrations of HCB and
b-HCH.
OCs and coffee intake had statistically independent effects
on the probability of having a KRAS-mutated PDA. p,p#-DDT
and PCBs 138 and 153 each remained statistically significant
after adding coffee to their respective models (Table II Models
1, 3, 4). Furthermore, the positive association between coffee
intake and KRAS mutations remained statistically significant
when four of the five OCs where in the models, and the ORs
significantly increased with increasing coffee consumption (all
four P-trend , 0.01) (Table II, Models 2–5). Further adjusting
by diabetes tended to decrease slightly the association between
coffee and KRAS and to not materially affect the association
with OCs (Table II). The results were virtually unaltered when
pancreatitis or peptic ulcer was included in the models instead
of diabetes.
When p,p#-DDT, PCB 153 and coffee intake were included
in the same model (along with age, sex, alcohol and cholestatic
syndrome), all three exposures were statistically significant.
Again, only the mid-tertile of p,p#-DDT was strongly
associated with KRAS mutation status. The ORs for the mid-
tertile and upper tertile of PCB 153 were .7 and 22,
respectively (P-trend 5 0.007), and the ORs for coffee intake
were 3, 8 and 12 (P-trend 5 0.016) (Table III, Model 1).
Coffee and PCB 138 were both significantly associated with
KRAS status when adjusted by each other and further adjusted
by p,p#-DDE (Table III, Model 2). When models were adjusted
by pancreatitis rather than diabetes, the associations decreased
only slightly, e.g. in Model 2, the P-values for PCB 138 and
coffee intake became 0.027 and 0.045, respectively. Alcohol
was also significantly associated with KRAS status, but the low
number of patients prevented further analyses (e.g. with more
than two categories of alcohol consumption).
All five OCs were statistically significantly associated with
the Asp mutation, but CIs were wide (Table IV). p,p#-DDT and
p,p#-DDE were also similarly associated with the mutation to
Val. Five of six P-values for trend for PCBs were ,0.05, but
models are adjusted by many factors and, again, precision was
low.
Concentrations of p,p#-DDT and p,p#-DDE were signifi-
cantly higher among the 103 cases of pancreatic cancer than
among the 27 controls (P 5 0.014 and 0.002, respectively).
The ORs for the mid and upper tertiles of p,p#-DDT were 4.2
and 7.3, respectively (P 5 0.003), whereas for p,p#-DDE, they
were 1.8 and 4.5, respectively (P 5 0.029). Levels of the two
compounds were statistically significantly higher in KRAS-
mutated cases than in controls: the ORs for the mid and upper
tertiles of p,p#-DDT were 7.7 and 10.2, respectively (P 5
0.002), whereas for p,p#-DDE they were 4.2 and 8.4,
respectively (P 5 0.007). With ORs for the upper tertile 3,
they were slightly higher (but statistically non-significant) in
KRAS wild-type cases than in controls. Concentrations of PCBs
were slightly (and again statistically non-significantly) higher
in cases (particularly, KRAS-mutated cases) than controls.
Analyses did not unveil any significant interaction between
OCs and age, gender, coffee, alcohol or tobacco consumption,
diabetes or other diseases or among OCs themselves, but
sample sizes were often small.
Discussion
We found that PDA patients whose tumours harboured a KRAS
mutation had higher concentrations of p,p#-DDT, p,p# DDE
and PCBs 138, 153 and 180 than cases with wild-type KRAS,
but differences were statistically significant only for p,p#-DDT
and PCBs 138 and 153, and the dose–response pattern was
approximately linear only for congener 138. These patterns
may be deemed to suggest that the associations are spurious.
Although it is biologically plausible that DDT shows non-
linear carcinogenic effects at low doses (50,51), interactions
between OC and unmeasured factors are likely and may result
in non-linear patterns; they need to be explored in large studies.
Our use of ROC curves to dichotomize OC concentrations is
just a contribution to the exploration of such response patterns.
The positive relationship between coffee intake and KRAS
mutations remained significant when four of the five OCs
where in the models, and ORs increased with increasing coffee
consumption. When two OCs (p,p#-DDT and PCBs 138 or
153) and coffee intake were included in the same model, both
compounds and coffee remained strongly associated to KRAS
mutations. p,p#-DDT, p,p# DDE and PCBs 138 and 153 were
similarly associated with the two most prevalent mutations, to
valine and to aspartic acid. Adjusting by past medical
conditions (notably, diabetes and pancreatitis) tended to
decrease slightly the association between coffee and KRAS
mutation status and not to materially affect the association
between OCs and KRAS. These results were not confounded by
alcohol and tobacco consumption.
The study size was small and many of our estimates were
statistically imprecise. Size also limited the number of variables
that models could account for. However, data had enough
power to detect associations of relevant magnitude and
scientific relevance. Furthermore, this is the largest study on
OCs and genetic alterations in pancreatic cancer and one of the
largest with analyses on OCs and tumour DNA in any type of
cancer (9,20,21,40). Findings hence deserve to encourage
Organochlorines, coffee and KRAS mutations in pancreatic cancer
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further studies, e.g. on the relationships between OCs and
somatic mutations in sporadic cancers. Large prospective
studies that collected blood many years before diagnosis could
refute or replicate our findings if they are able to avoid
selection biases caused by low retrieval of tumour specimens,
a requirement for KRAS and other (but not all) genetic analyses
(56,61). The timing of blood draw and pathophysiologic
changes common in PDA (e.g. lipid mobilization and
cholestasis) could not bias comparisons between KRAS-
mutated and wild-type cases because: (i) there were only small
differences between the two types of cases in symptoms at
presentation (e.g. constitutional and cholestatic syndromes), in
tumour stage or in other clinical variables (54,56,61,68) and (ii)
based on previous research (61,63,65), such factors were
Table I. Serum concentrations of OCs in cases of PDA with and without a mutation in the KRAS oncogenea
Compound All cases (N 5 103) KRAS Model 1b (N 5 103) Model 2c (N 5 103)
Mutated (N 5 81) Wild-type (N 5 22) P OR 95% CI Pd OR 95% CI Pd
p,p#-DDT
Mean  SD 626.6  1029.7 692.0  1108.9 385.7  623.2 0.016e
Median 354.7 414.8 114.9
Tertiles
224 41 (39.8%) 26 (32.1%) 15 (68.2%) 0.001f 1.0 0.007 1.0 0.009
225–614 34 (33.0%) 33 (40.7%) 1 (4.5%) 29.8 3.3–270.0 30.0 3.2–283.7
.614 28 (27.2%) 22 (27.2%) 6 (27.3%) 2.8 0.8–9.4 2.8 0.8–9.9
Dichotomous
190 34 (33.0%) 19 (23.5%) 15 (68.2%) ,0.001f 1.0 ,0.001 1.0 ,0.001
.190 69 (67.0%) 62 (76.5%) 7 (31.8%) 9.1 2.9–28.4 9.2 2.8–30.1
p,p#-DDE
Mean  SD 4078.1  4417.6 4368.0  4827.5 3010.7  2119.1 0.342e
Median 2706.8 2721.4 2548.3
Tertiles
1652 31 (30.1%) 22 (27.2%) 9 (40.9%) 0.429f 1.0 0.146g 1.0 0.190g
1653–4384 39 (37.9%) 31 (38.3%) 8 (36.4%) 1.8 0.6–5.8 1.7 0.5–5.4
.4384 33 (32.0%) 28 (34.6%) 5 (22.7%) 2.6 0.7–9.7 2.4 0.6–9.5
Dichotomous
4750 74 (71.8%) 55 (67.9%) 19 (86.4%) 0.112f 1.0 0.081 1.0 0.084
.4750 29 (28.2%) 26 (32.1%) 3 (13.6%) 3.4 0.9–13.7 3.7 0.8–16.2
PCB 138
Mean  SD 255.1  203.5 268.1  172.1 207.6  291.8 0.014e
Median 221.0 260.8 152.2
Tertiles
167 40 (38.8%) 27 (33.3%) 13 (59.1%) 0.073f 1.0 0.012g 1.0 0.004g
168–299 26 (25.2%) 21 (25.9%) 5 (22.7%) 2.8 0.8–10.0 3.0 0.8–11.3
.299 37 (35.9%) 33 (40.7%) 4 (18.2%) 5.1 1.4–18.5 7.2 1.8–28.8
Dichotomous
302 67 (65.0%) 48 (59.3%) 19 (86.4%) 0.023f 1.0 0.020 1.0 0.007
.302 36 (35.0%) 33 (40.7%) 3 (13.6%) 4.9 1.3–18.5 6.9 1.7–27.9
PCB 153
Mean  SD 297.3  200.5 314.1  209.6 235.3  150.7 0.087e
Median 233.5 244.1 181.0
Tertiles
187 37 (35.9%) 25 (30.9%) 12 (54.5%) 0.045f 1.0 0.003g 1.0 0.001g
188–313 31 (30.1%) 24 (29.6%) 7 (31.8%) 2.4 0.8–7.9 2.7 0.8–9.5
.313 35 (34.0%) 32 (39.5%) 3 (13.6%) 9.2 2.0–42.3 15.4 2.9–82.3
Dichotomous
305 67 (65.0%) 48 (59.3%) 19 (86.4%) 0.023f 1.0 0.009 1.0 0.004
.305 36 (35.0%) 33 (40.7%) 3 (13.6%) 6.7 1.6–27.50 9.3 2.1–41.6
PCB 180
Mean  SD 314.1  224.2 328.7  240.7 260.4  140.0 0.489e
Median 239.6 251.9 229.1
Tertiles
186 35 (34.0%) 29 (35.8%) 6 (27.3%) 0.185f 1.0 0.222 1.0 0.220
187–322 34 (33.0%) 23 (28.4%) 11 (50.0%) 0.5 0.1–1.6 0.5 0.2–1.8
.322 34 (33.0%) 29 (35.8%) 5 (22.7%) 1.4 0.3–5.5 1.6 0.4–6.7
Dichotomous
475 85 (82.5%) 64 (79.0%) 21 (95.5%) 0.111f 1.0 0.074 1.0 0.053
.475 18 (17.5%) 17 (21.0%) 1 (4.5%) 7.0 0.8–59.3 8.5 1.0–74.6
aValues of OCs are corrected by total lipids and expressed in nanograms per gram lipid.
bModel 1: ORs adjusted by age, sex and alcohol consumption.
cModel 2: ORs adjusted by age, sex, alcohol consumption and the appropriate signs and symptoms: p,p#-DDT adjusted by the constitutional syndrome; p,p#-DDE,
PCB 138, PCB 153 and PCB 180 adjusted by the cholestatic syndrome (61).
dUnless otherwise specified, P-value derived from Wald test.
eMann–Whitney U-test.
fFisher’s exact test.
gTest for linear trend (multivariate analogue of Mantel’s extension test).
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accounted for in the analyses. Thus, ORs for OCs increased
slightly when controlling for symptoms (Table I, Model 2)
(61). Results shown do not adjust for smoking because it is
weakly or not associated with KRAS and OCs and, therefore, it
did not alter estimates (24); the same applies to a history of
peptic ulcer (67).
Having a small control group from a single hospital clearly
limits the case–control component of the analyses, but is
unlikely to bias the main conclusions. The primary purpose of
comparing the two types of PDA cases with the controls was to
explore the direction of the case–case association (7,8,72,74);
such results suggest that mutated cases had higher levels than
controls, whereas wild-type cases and controls had similar con-
centrations. Patients from the different hospitals did not differ
in their clinical and sociodemographic characteristics (68);
they also had very similar mutation rates and levels of OCs.
This report should not be seen as an independent replica-
tion of our previous findings on OCs (7) since half of the
patients were the same. However, the improvement over
the initial report in methods and analyses is highly relevant.
With improved methods (56), the present results largely
confirm previous findings on OCs, coffee intake and alcohol
consumption (7,8,54).
The results are compatible with the hypothesis that in PDA
OCs help activate KRAS or provide a growth advantage to
KRAS-mutated cells. DDT and the more oestrogenic PCBs are
established animal carcinogens. However, as previously
hypothesized (5,7,8), the association between OCs and KRAS
need not be through a directly mutagenic mechanism. First,
OCs are enzyme inducers and may thus enhance enzymes that
Table II. The joint effect of each OC and coffee consumption on the
probability of a KRAS-mutated (versus KRAS wild-type) tumoura
Model Exposures ORb 95% CI Pc ORd 95% CI Pc
1 p,p#-DDT
224 1.0 0.011 1.0 0.009
225–614 33.9 3.3–353.7 44.0 3.8–512.8
.614 3.0 0.7–12.2 3.8 0.8–17.5
Coffee intake
Non-regular
drinkers
1.0 0.074e 1.0 0.097e
1–7 cups/week 3.8 0.7–19.8 3.6 0.7–19.6
8–14 cups/week 3.0 0.5–18.8 2.5 0.4–16.0
15 cups/week 5.2 1.0–26.7 5.0 0.9–27.8
2 p,p#-DDE
1652 1.0 0.169e 1.0 0.181e
1653–4384 2.2 0.6–8.2 2.2 0.6–8.0
.4384 2.6 0.6–10.7 2.5 0.6–10.5
Coffee intake
Non-regular
drinkers
1.0 0.008e 1.0 0.010e
1–7 cups/week 4.6 1.0–20.9 4.6 1.0–21.1
8–14 cups/week 6.4 1.3–31.5 6.2 1.2–31.1
15 cups/week 9.5 1.9–47.6 9.4 1.8–48.0
3 PCB 138
167 1.0 0.005e 1.0 0.006e
168–299 3.8 0.9–16.6 3.8 0.9–16.5
.299 8.1 1.8–36.9 8.0 1.8–36.6
Coffee intake
Non-regular
drinkers
1.0 0.009e 1.0 0.011e
1–7 cups/week 2.8 0.6–13.6 2.8 0.6–13.9
8–14 cups/week 6.9 1.3–35.5 6.4 1.2–33.2
15 cups/week 8.2 1.5–44.1 8.1 1.5–44.4
4 PCB 153
187 1.0 0.001e 1.0 0.001e
188–313 5.0 1.1–21.4 5.3 1.2–23.5
.313 22.1 3.4–143.6 27.3 3.8–196.7
Coffee intake
Non-regular
drinkers
1.0 0.007e 1.0 0.010e
1–7 cups/week 3.8 0.7–20.3 3.9 0.7–21.8
8–14 cups/week 9.5 1.7–55.0 8.4 1.4–48.6
15 cups/week 11.1 1.9–66.6 10.5 1.7–65.1
5 PCB 180
186 1.0 0.240 1.0 0.180
187–322 0.6 0.2–2.2 0.6 0.2–2.2
.322 2.0 0.4–9.0 2.3 0.5–11.1
Coffee intake
Non-regular
drinkers
1.0 0.009e 1.0 0.013e
1–7 cups/week 4.5 1.0–20.5 4.6 1.0–21.9
8–14 cups/week 7.4 1.5–36.7 6.9 1.4–35.1
15 cups/week 8.5 1.8–40.7 8.5 1.7–42.7
aValues of OCs are corrected by total lipids and expressed in nanograms per
gram lipid (N 5 95).
bORs for the OC and for coffee are mutually adjusted for; ORs are also adjusted
by age, sex, alcohol consumption and the appropriate signs and symptoms:
p,p#-DDT adjusted by constitutional syndrome; p,p#-DDE, PCB 138, PCB 153
and PCB 180 adjusted by cholestatic syndrome.
cUnless otherwise specified, P-value derived from Wald test.
dFurther adjusted by diabetes.
eTest for linear trend (multivariate analogue of Mantel’s extension test).
Table III. The statistically independent effect of two OCs and coffee on the
probability of a KRAS-mutated (versus KRAS wild-type) tumoura
Exposures ORb 95% CI P
Model 1
p,p#-DDT
224 1.0 0.042c
225–614 16.2 1.6–167.0
.614 0.8 0.2–4.1
PCB 153
187 1.0 0.007d
188–313 7.5 1.2–45.8
.313 22.1 2.3–213.6
Coffee intake
Non-regular drinkers 1.0 0.016d
1–7 cups/week 3.1 0.5–20.7
8–14 cups/week 8.3 1.0–70.5
15 cups/week 11.9 1.6–88.9
Alcohol consumption
No and occasional 1.0 0.025c
Moderate and heavy 6.7 1.3–35.6
Model 2
p,p#-DDE
1652 1.0 0.693c
1653–4384 1.8 0.5–7.3
.4384 1.3 0.3–7.0
PCB 138
167 1.0 0.011d
168–299 3.9 0.9–17.3
.299 7.5 1.5–36.8
Coffee intake
Non-regular drinkers 1.0 0.007d
1–7 cups/week 3.0 0.6–14.8
8–14 cups/week 6.9 1.3–36.7
15 cups/week 10.0 1.7–58.9
Alcohol consumption
No and Occasional 1.0 0.025c
Moderate and Heavy 5.1 1.2–21.1
aValues of OCs are corrected by total lipids and expressed in nanograms per
gram lipid (N 5 95).
bOR adjusted by age, sex and cholestatic syndrome.
cWald test.
dTest for linear trend (multivariate analogue of Mantel’s extension test).
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activate the carcinogens ultimately responsible for mutating
KRAS. Second, as tumour promoters and possibly endocrine
disruptors (34,52), OCs may also be relevant in other
mechanistic scenarios involving interference with cell-cycle
checkpoints and apoptosis, alterations in gene expression or
other non-genotoxic and epigenetic effects (5,7,33–36,48–
50,52,53). DDT and its metabolites, for instance, stimulate
gene expression through various transcription factors and
multiple response elements, including the mitogen-activated
protein kinases (MAPKs) (49). Activated KRAS also engages
multiple effecter pathways, notably MAPK (1–4).
We measured blood concentrations of only a few OC among
the many that are commonly found in humans (38);
furthermore, concentrations of environmental chemicals are
often correlated, i.e. subjects with high levels of some
substances are likely to have higher values of other compounds
as well (58,62). Thus, unmeasured contaminants (OC or non-
OC) could be partly responsible for the observed associations.
Increases in the risk of PDA have been associated with
exposure to chlorinated organics but, overall, the evidence is
limited (7,9,39–43,46,75,76). Surprisingly, only three studies
have used biomarkers of exposure to OC (7,9,39,40); a positive
association between serum DDE levels and pancreatic cancer
risk remains to be published (D. Garabrant, personal
communication). Studies that do not use biomarkers are likely
to misclassify personal cumulative concentrations of OCs since
OC exposure usually occurs inadvertently throughout the
lifecourse (36,38,47,48,77–79). Serum levels provide accurate
and specific estimates of individual internal dose at a time
window that is aetiologically relevant for KRAS mutations in
PDA (5,7,29). Background environmental exposure (mostly
from foods contaminated at generally low doses) is usually
a more important source of OC than occupation (25,47). We
are conducting specific analyses to elucidate such sources in
our study subjects.
In recent years, higher concentrations of several common
OCs—including DDT, DDE and PCBs—have been associated
with an increased prevalence of health disorders as diabetes,
obesity and several other components of the metabolic
syndrome (36,48,77–80); remarkably, all such disorders are
also under scrutiny as risk factors for pancreatic cancer
(42,43,81). Similarly, higher concentrations of persistent
organic pollutants (POPs), especially OC pesticides, have been
found positively associated with periodontal disease (82).
Independently, periodontal diseases have also been associated
with the risk of pancreatic and other cancers (83). Thus, our
findings suggest that POPs might explain observed associations
between some disorders (diabetes, obesity, metabolic syn-
drome and periodontal diseases) and pancreatic cancer risk.
Findings are relevant not only for pancreatic cancer but also for
research on other health effects of POPs as well.
The effects of OCs and coffee were not mutually
confounded, i.e. they were statistically independent; they
might also be biologically independent: in PDA the intake of
caffeine or other coffee compounds may favour the occurrence
or persistence of KRAS mutations through biological pathways
different from OCs. Alcohol also independently increased the
odds of a KRAS-mutated PDA (as always, versus that of
a KRAS wild-type tumour), but detailed analyses of alcohol
were hampered by sample size. Mechanistic scenarios for these
Table IV. Concentrations of OCs and KRAS mutation spectra
Valinea (N 5 17) Aspartic acida (N 5 17) Valine versus wild-typeb Aspartic acid versus wild-typec
OR 95% CI Pd OR 95% CI Pd
p,p#-DDT
224 3 (17.7%) 3 (17.6%) 1.0 0.032 1.0 0.028
225–614 9 (52.9%) 8 (47.1%) 1026.6 5.7–UH 260.4 3.6–19 015
.614 5 (29.4%) 6 (35.3%) 20.3 0.7–618.5 17.1 1.4–210
p,p#-DDE
1652 3 (17.6%) 3 (17.6%) 1.0 0.049e 1.0 0.022e
1653–4384 6 (35.3%) 5 (29.4%) 4.1 0.5–31.6 2.6 0.3–21.2
.4384 8 (47.1%) 9 (53.0%) 11.6 1.0–133.9 18.0 1.6–208
PCB 138
167 3 (17.6%) 4 (23.5%) 1.0 0.045 1.0 0.026e
168–299 8 (47.1%) 4 (23.5%) 47.4 1.9–1182.5 2.5 0.3–22.3
.299 6 (35.3%) 9 (53.0%) 29.4 1.3–670.4 8.2 1.3–52.5
PCB 153
187 5 (29.4%) 2 (11.8%) 1.0 0.049e 1.0 0.003e
188–313 7 (41.2%) 5 (29.4%) 2.2 0.3–14.4 6.0 0.6–64.2
.313 5 (29.4%) 10 (58.8%) 20.1 0.8–496.4 42.7 3.4–531
PCB 180
186 7 (41.2%) 3 (17.6%) 1.0 0.440 1.0 0.038e
187–322 6 (35.3%) 4 (23.5%) 0.3 0.0–2.4 1.0 0.1–8.5
.322 4 (23.5%) 10 (58.8%) 1.0 0.1–11.5 8.3 0.8–82.1
Comparison of cases mutated to valine and to aspartic acid against wild-type cases. Values of OCs are corrected by total lipids and expressed in nanograms per gram
lipid. UH indicates unquantifiably high.
aKRAS codon 12 wild-type: glycine (GGT); mutation to valine: GTT (transversion); mutation to aspartic acid: GAT (transition).
bORs adjusted by age, sex, coffee intake, alcohol consumption and the appropriate signs and symptoms: p,p#-DDT adjusted by constitutional syndrome; p,p#-DDE,
PCB 138, PCB 153 and PCB 180 adjusted by cholestatic syndrome.
cORs adjusted by age, sex, coffee intake, diabetes and the appropriate signs and symptoms: p,p#-DDT adjusted by constitutional syndrome; p,p#-DDE, PCB 138,
PCB 153 and PCB 180 adjusted by cholestatic syndrome.
dUnless otherwise specified, P-value derived from Wald test.
eTest for linear trend (multivariate analogue of Mantel’s extension test).
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observations have been previously proposed (5,7,8,53,54,74).
Ras proteins play a central role in conferring on tumour cells
the capability of being self-sufficient in growth signals by
virtue of their biochemical function as activators of in-
tracellular effecter pathways that control transcription, cell
survival and the actin cytoskeleton. These pathways form
a signalling network that enables the cell to interpret growth-
promoting signals in a context-dependent manner (2,30,84).
Ras oncogenes facilitate neoplastic conversion by stimulating
tumour cell growth, survival and motility. The role of ras in
malignant transformation extends beyond these cell-intrinsic
effects to include the establishment of a pro-tumorigenic host
environment. Ras-induced secretion of the chemokine in-
terleukin-8 elicits a local inflammatory reaction that is critical
for neovascularization and sustained tumour growth. The ras
oncogene hence promotes tumour–host interactions that are
essential for cancer progression (30,85). Therefore, the study
findings may have mechanistic implications for other neo-
plasms with a high frequency of ras mutations (28); they are
relevant for scientists working on somatic mutations in human
carcinogenesis, OCs or pancreatic cancer, and they contribute
to the scant literature on the role of gene–environment
interactions in the poorly understood aetiopathogenesis of
PDA. Of course, replication is required before mechanistic
or clinical implications, if any, are further considered
(33–36,48,77).
In conclusion, p,p#-DDT, PCBs and coffee may have
independent roles in the aetiopathogenesis of PDA by
influencing KRAS activation, acquisition or persistence,
perhaps through indirect, non-genotoxic or epigenetic mecha-
nisms. Given that KRAS mutations are the most frequent
abnormality of oncogenes in human cancers, and the common,
lifelong accumulation of OCs, refutation or replication of the
findings is required. If replicated by independent and valid
studies, the results could open new paths to better understand
the aetiology of pancreatic and other cancers. They might also
help clarify other health effects of OCs.
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